SnagRx vs Hers: Compounded pricing vs FDA-approved Wegovy® options
The core difference in SnagRx vs Hers is whether you prefer lower, compounded pricing with a price lock or FDA-approved brand-name medication with a personalized care team. Early verdict: choose SnagRx for the lowest annual-plan compounded price and a locked rate across titration; choose Hers if you want FDA-approved Wegovy and ongoing dose check-ins.
How SnagRx and Hers differ on medication type and regulatory status
SnagRx supplies compounded semaglutide (not FDA-approved as a finished product) and compounded tirzepatide, with explicit regulatory language that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. Hers offers FDA-approved Wegovy, a brand-name semaglutide, and states it does not provide compounded medications. This is the clearest distinction when comparing SnagRx vs Hers.
Pricing models and membership requirements
SnagRx advertises compounded semaglutide from $69/month and tirzepatide from $119/month on a 12-month plan; month-to-month equivalents are $99 and $149. The $69 and $119 figures are the 12-month plan rates and SnagRx emphasizes the rate is locked flat at every dose and at renewal. Hers lists Wegovy from $149/month and other brand options from higher price points, and notes an active Hers Weight Loss Membership is required; membership is $39 for the first month and auto-renews at $149/month thereafter, and medication is not available without an active membership. When comparing SnagRx vs Hers, SnagRx targets cost-driven patients seeking predictable all-in pricing while Hers bundles FDA-approved medication with a paid membership model.
View Hers FDA-approved options
Clinical access, clinician review, and care model
SnagRx uses a clinician network named OpenLoop Health that it says typically reviews intake within five hours and always within 24, with prescriptions filled by named US 503A compounding pharmacies. SnagRx includes telemed visits and clinician review in the price and states clinicians retain the decision to prescribe compounded GLP-1s. Hers highlights a personalized care team with ongoing dose check-ins; Hers notes prescriptions are available when a licensed clinician determines they are medically appropriate and that availability is not in all 50 states. Both providers require a clinician decision to prescribe, but SnagRx emphasizes rapid reviews and named compounding partners while Hers emphasizes ongoing dose management with a care team for brand medications.
Shipping, refunds, and guarantees
SnagRx states next-day UPS/FedEx delivery in temperature-controlled packaging and a full refund if the prescription is declined; it also mentions a 6-month weight-loss guarantee with terms applied. Hers does not provide captured landing-page details about shipping speed or refunds in the supplied evidence, though it states medication is billed separately and membership is required. For SnagRx vs Hers this means SnagRx provides captured claims about next-day shipping and specific refund/guarantee terms while Hers focuses on the brand medication and care team.
Direct comparison table
| Criteria | SnagRx | Hers |
|---|---|---|
| Medication type | Compounded semaglutide and tirzepatide | FDA-approved Wegovy and other brand options, not compounded |
| Starting price (captured) | From $69/mo semaglutide on 12-month plan | Wegovy from $149/mo; membership required |
| Membership required | No monthly membership required | Yes, active membership required |
| Price structure | 12-month plan locks price flat at every dose | Price includes medication only; membership billed separately |
| Clinician and pharmacy | OpenLoop Health clinician network; named US 503A pharmacies | Licensed clinicians with personalized care team; not all states available |
| Regulatory note | Compounded medications not FDA-approved | Offers FDA-approved brand medication |
Which provider is better for common priorities?
Cost and predictable titration pricing
If your priority is lowest annual-plan compounded cost and a locked rate as doses escalate, SnagRx positions itself for cost-driven patients with semaglutide from $69/month on the 12-month plan and a price lock at every dose. The $69/$119 rates require the 12-month commitment; month-to-month costs are higher.
FDA-approved medication and ongoing care
If you prioritize FDA-approved brand-name medication and a personalized care team with ongoing dose check-ins, Hers offers Wegovy and emphasizes a care team model. Hers also requires an active membership, which affects total monthly billing and access to medication according to the captured evidence.
Check SnagRx pricing and plan details
Final take on SnagRx vs Hers
SnagRx vs Hers is a tradeoff between compounded, lower-cost plans with price-locking and named compounding partners (SnagRx) and FDA-approved, brand-name Wegovy with a personalized care team but a membership requirement (Hers). SnagRx is explicit that compounded medications are not FDA-approved; Hers is explicit that it offers FDA-approved Wegovy and does not offer compounded products. Verify state availability and membership terms with Hers and the 12-month commitment for SnagRx before enrolling.
Choose SnagRx if…
you prioritize bottom-of-market annual-plan pricing for compounded semaglutide (from $69/month on a 12-month plan), want a price locked at every dose, and value named US 503A pharmacies plus rapid clinician review.
Choose Hers if…
you want FDA-approved Wegovy with a personalized care team and ongoing dose check-ins and accept an active membership requirement for access to brand medication.